MedTrace Logo

A Study to Investigate the Pharmacokinetics, Safety, Tolerability, and Efficacy of AZD0780 With Ezetimibe Combinations in Healthy Adults With Elevated LDL-C.

NCT06742853 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 81

Last updated 2025-11-10

No results posted yet for this study

Summary

The main aim of this study is to assess the effects of AZD0780 when added on top of ezetimibe or ezetimibe and rosuvastatin or ezetimibe and bempedoic acid.

Conditions

Interventions

DRUG

AZD0780

AZD0780 tablet will be administered orally.

DRUG

Ezetimibe

Ezetimibe tablet will be administered orally.

DRUG

Rosuvastatin

Rosuvastatin tablet will be administered orally.

DRUG

Bempedoic Acid

Bempedoic Acid tablet will be administered orally.

DRUG

Placebo

Placebo will be administered orally.

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-12-20
Primary Completion
2025-10-29
Completion
2025-10-29
FDA Drug
Yes

Countries

  • United States
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06742853 on ClinicalTrials.gov